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strains and showed low cytotoxicity in CHO cells indicating 
a high degree of selectivity. In  E. coli reporter strains, NCD9 
induced the DegP response pathway as well as the SOS re-
sponse, suggesting interaction with both the cell envelope 
and DNA metabolism.  Conclusions: The results presented in 
this report indicate the potential of this new class of cationic 
antimicrobial compounds for the design of potent and selec-
tive antibacterials with low cytotoxicity. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 The problem of microbial drug resistance has reached 
a global dimension and an alarming magnitude. Epidem-
ic antibiotic resistance has been reported in numerous 
pathogens, including the global pandemic of methicillin-
resistant  Staphylococcus aureus (MRSA) infection, and 
epidemic increases of multidrug-resistant and increas-
ingly pan-resistant strains of Gram-negative bacteria, 
such as  Pseudomonas aeruginosa and  Acinetobacter bau-
mannii  [1–3] . The systemic or topical treatment of the in-
creasing number of infections caused by resistant or mul-
tiresistant bacteria demands new antibiotics, preferably 
from new structural classes and with new mechanisms of 
action. However, the difficulty of finding and developing 
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 Abstract 
 Objectives: In this study, the in vitro antimicrobial activity 
and spectrum of new dimeric compounds derived from the 
cyanobacterial alkaloid nostocarboline were investigated. 
The mechanism of action and selectivity to bacteria were 
studied and compared to the cationic antiseptic chlorhex-
idine.  Methods:  Minimal inhibitory concentrations were 
 determined against clinical isolates and against a panel of 
microbial reference strains using the CLSI microdilution 
method. Bacterial membrane damage was addressed by 
measuring ATP leakage and the mode of action was investi-
gated in  Escherichia coli reporter strains. Selectivity was test-
ed by a cytotoxicity assay using MTS.  Results: The antimicro-
bial potency of dimers varied with length of the hydropho-
bic linker. The most potent compounds, NCD9 and NCD10, 
had a C10 and C12 linker, respectively, and showed strong 
activity against Gram-positive bacteria, notably methicillin-
resistant  Staphylococcus aureus strains. Similar to chlorhex-
idine, these compounds showed a rapid concentration- 
dependent bactericidal effect, which correlated with mem-
brane damage as indicated by ATP leakage. NCD9, in contrast 
to NCD10 and chlorhexidine, lacked activity against yeast 
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new antibacterial agents is underlined by the fact that 
only two new chemical classes were brought into medical 
use over the past 35 years: the oxazolidinones (with line-
zolid as the only representative so far) and daptomycin 
 [4] .
 Natural products have historically been a rich source 
of antimicrobial compounds and roughly 50% of all 
agents on the market addressing infectious diseases are 
natural products or derivatives thereof  [5] . Cyanobacteria 
have been shown to be a prolific source of bioactive com-
pounds  [6–8] . The cyanobacterial metabolite nostocar-
boline has potent algicidal activity, while antibacterial ac-
tivity is weak or absent  [7–9] . This secondary metabolite, 
originally isolated from the freshwater cyanobacterium 
 Nostoc 78–12A  [9] , has been demonstrated to inhibit the 
growth of other algae  [7] , a feature (alloleopathy) that is 
commonly found in cyanobacterial metabolites  [8] . Re-
cently, it was demonstrated that nostocarboline is active 
against the parasite  Plasmodium falciparum and ho-
modimers of nostocarboline with potent antiplasmodial 
activity were synthesized  [10, 11] . The mode of action of 
nostocarboline against  Plasmodium was speculated to be 
correlated to its algicidal activity, which is unclear at pres-
ent. Dimerization of cationic natural products often leads 
to enhanced biological activity and the resulting bisbi-
cationic compounds are clinically used as antimicrobial 
agents  [10] . Here, we report on the antibacterial activity 
and spectrum of a series of nostocarboline dimers as well 
as on investigations on the mode of action and selectivity 
of these compounds. Since dimerization of nostocarbo-
line leads to bisbicationic compounds, we chose the mem-
brane-acting bisbiguanide antiseptic chlorhexidine as a 
comparator. In addition, ciprofloxacin was used as a ref-
erence antibiotic and as an example of an antibacterial 
with a distinct intracellular target.
 Material and Methods  
 Antibacterial Compounds 
 The synthesis of nostocarboline and its homodimers has been 
reported elsewhere  [10, 11] .
 Ciprofloxacin and chlorhexidine were obtained from Sigma-
Aldrich.
 Microbial Strains 
 Strains used in this study were from the strain collection of 
Actelion Pharmaceuticals Ltd. Most of the clinical isolates were 
collected between 2001 and 2006 from various European and US 
hospitals. Reference strains were obtained from the American 
Type Culture Collection (ATCC). All strains were stored at –80  °  C 
in 20% glycerol cultures. A primary panel of quality control 
strains from the ATCC as well as selected clinical isolates were 
used ( table 1 ). Selected compounds were also tested against a pan-
el of 20 MRSA clinical isolates. Genetically modified  Escherichia 
coli  strains were constructed in-house and used in reporter assays 
(see below). The stress response due to either DNA damage or 
damage to the cell envelope was assayed in strains derived from 
MG1655 (CGSC 7740). The  luxCDABE operon of  Photorhabdus 
luminescens  [12] was linked to the trimethoprim resistance mark-
er  dfrA1 from ColE1::Tn7 (DSMZ 3872) and then integrated in 
single copy in the chromosome using standard genetic procedures 
at the  lac locus generating a   lacZ ::( luxCDABE - dfrA1 ) strain. The 
 sulA or  degP promoter region were PCR-amplified from the chro-
mosome and fused by overlapping PCR to the gentamicin resis-
tance cassette  aph (2’)- aac (6’) from  Enterococcus faecalis (ATCC 
51299). Finally, the promoter region upstream of  luxC was re-
Table 1. M ICs (mg/l) by microdilution method against a panel of bacterial and yeast strains
C ompounds
NCD1 NCD2 NCD3 NCD4 NCD5 NCD6 NCD7 NCD8 NCD9 NCD10 NC CIP CHL
S. aureus ATCC 29213 16 4 32 8 >32 32 8 2 0.25 0.25 >32 0.25 0.25
S. aureus A-798 (MRSA) 16 8 >32 8 32 8 16 8 0.5 0.5 >32 >32 0.25
E. faecium A-949 (VRE) 32 8 32 8 32 32 32 16 2 1 >32 >32 2
S. pneumoniae ATCC 49619 >32 >32 >32 32 >32 >32 >32 32 4 4 >32 1 4
H. influenzae A-921 >32 >32 >32 >32 >32 >32 >32 >32 8 32 >32 ≤0.03 0.25
E. coli ATCC 25922 32 >32 >32 >32 >32 >32 32 8 8 8 >32 ≤0.03 0.125
E. coli Ec2085 2 8 8 >32 >32 1 1 0.5 0.5 1 >32 0.004 0.125
A. baumannii T-6474 32 32 >32 >32 >32 >32 >32 32 16 8 >32 >32 16
P. aeruginosa ATCC 27853 32 >32 >32 >32 >32 >32 >32 >32 32 >32 >32 0.5 4
S. cerevisiae A-136 >32 >32 >32 >32 >32 >32 >32 >32 >32 1 >32 >32 4
C. albicans T-3419 >32 32 >32 >32 >32 >32 >32 >32 >32 0.5 >32 >32 4
VR E = Vancomycin-resistant Enterococcus; NC = nostocarboline; CIP = ciprofloxacin; CHL = chlorhexidine.
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placed with either the  sulA or  degP promoter following the proce-
dure by Datsenko and Wanner  [13] . The reporter strains were also 
made more susceptible to the effect of small molecules by intro-
ducing  tolC  [14] or  rfaC disruptions (Actelion strain collection) 
using generalized P1 transduction  [15] resulting in strains Ec2376 
[  tolC   rfaC   lacZ ::( sulA’ -‘  luxCDABE )] and Ec2297 [  tolC 
  lacZ ::( degP’ -‘  luxCDABE )]. An isogenic   tolC   rfaC mutant 
(Ec2085) was used for the determination of minimal inhibitory 
concentrations (MICs).
 Determination of MICs  
 Stock solutions of compounds were made in DMSO (5 mg/ml). 
MICs were determined by a broth microdilution assay following 
the guidelines of the Clinical Laboratory Standards Institute 
(CLSI, formerly NCCLS)  [16] . Cation-adjusted Mueller-Hinton II 
broth (CA-MHB) was used as the basic test medium (Becton 
Dickinson and Co., Sparks, Md., USA), which was supplemented 
as appropriate for fastidious organisms  [16] .
 Time-Kill Assays 
 Exponential-phase  S. aureus ATCC 29213 was diluted in fresh 
CA-MHB at approximately 10 7 colony-forming units (cfu) per ml. 
After 1 h of incubation with shaking at 37   °   C, compounds were 
added at a concentration matching 4 ! and 16 ! the MIC. After 
further incubation for 1 and 4 h, viable bacterial counts were de-
termined by plating appropriate dilutions on Mueller-Hinton 
agar plates (Becton Dickinson and Co., Sparks, Md., USA), fol-
lowed by determination of the cfu after 24 h incubation at 37   °  C.
 ATP Release Assay 
 Leakage of cellular ATP was measured to investigate the effect 
of compounds on membrane integrity  [17] . Briefly, mid-exponen-
tial-phase  S. aureus cells were centrifuged and resuspended in 
PBS containing antibacterial compounds. After incubation for 20 
min at 37   °   C with shaking, suspensions were centrifuged again 
and the ATP concentration in the supernatant was determined 
using the BacTiter-Glo microbial cell viability assay kit (Promega, 
Madison,    Wisc.,    USA).    Untreated   cultures   served   as   the   nega-
tive control while 0.1% (w/w) SDS was used as the positive (mem-
branolytic) control.
 Stress Response Assays  
 For the stress response assays, plates (Costar 3882, Corning, 
Mass., USA) were prepared as described for MIC assays, except 
that 10 8 cells/ml were added to the compounds. Luminescence 
was read after 2 h of incubation at 30  °  C with the compounds and 
normalized to the cells present in the wells (nRLU). The induction 
of the stress response was expressed as the ratio of nRLU mea-
sured with compounds and nRLU with 1% DMSO.
 Cytotoxicity  
 Toxicity to eukaryotic cells was measured by using CHO-K1 
cells and an MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxyme-
thoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium] reduction as-
say (Promega, Madison, Wisc., USA). Briefly, 60,000 cells/well 
were grown in flat 96-well plates for 4 h. Compounds were added 
to the cells and incubated at 37   °   C. Cell viability was measured 
after 24 h by adding MTS Reagent (10%). After 2 h, optical den-
sity (OD) was measured at 490 nm with 630 nm as the reference 
wavelength using a spectrophotometer. 
 Results 
 Ten nostocarboline dimers ( fig. 1 ), synthesized with 
the aim of evaluating linker size and antibacterial prop-
erties, were tested against a panel of bacterial and yeast 
strains ( table 1 ). Monomeric nostocarboline, the biscat-
ionic antiseptic chlorhexidine and the fluoroquinolone 
antibiotic ciprofloxacin were used as comparators. While 
the nostocarboline monomer was not active at the tested 
concentrations, all dimers showed antimicrobial activity 
against at least one strain. Potency and antimicrobial 
spectrum varied with length and structure of the linker 
used to connect the monomers. Activities of dimers 
NCD1–NCD8, with linkers of equal or shorter than eight 
carbon units, were relatively weak. In contrast, NCD9 
and NCD10, with linear C10 and C12 linkers, respective-
ly, showed potent activity with MICs of less than 1 mg/l 
for many strains. Against Gram-positive bacteria ( S. au-
reus ,  Enterococcus faecium ,  Streptococcus pneumoniae ), 
these compounds were as potent as chlorhexidine, while 
against Gram-negative bacteria ( Haemophilus influen-
zae ,  A. baumannii ,  E. coli ,  P. aeruginosa ), they were less 
active. Potency increased again significantly in a perme-
able and efflux-deficient  E. coli mutant (Ec2085). Inter-
estingly, only NCD10 with the longest linker showed po-
tent activity against the yeast strains  Saccharomyces cere-
visiae and  Candida albicans .
 The two most active dimers, NCD9 and NCD10, were 
further challenged against a collection of 20 recent clini-
cal isolates of MRSA, most of which were resistant to
fluoroquinolones ( table 2 ). All strains were susceptible to 
NCD9 and NCD10 with MICs in the range of 0.125–
2 mg/l and 0.125–0.5 mg/l, respectively, similar in po-
tency to chlorhexidine.
 Time-dependent antibacterial killing was investigated 
in an MRSA strain ( table 3 ). At a concentration of 16 ! 
the MIC, both NCD9 and NCD10 showed a rapid reduc-
tion of viable bacteria ( 1 99% within 4 h), while at 4 ! the 
MIC, the effect was only static. A similar concentration-
Table 2. I n vitro activity against a set of 20 clinical isolates of 
MRSA (MICs in mg/l)
Compound MIC 50% MIC 90% Range
NCD9 0.25 2 0.125–2
NCD10 0.25 0.5 0.125–0.5
Ciprofloxacin 32 >32 0.06 to >32
Chlorhexidine 0.125 0.5 0.06–0.5
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dependent killing effect was also observed with chlorhex-
idine.
 Although the mode of action of chlorhexidine and 
other polycationic antiseptics is not clear in all details, 
disruption of the plasma membrane seems to be an im-
portant factor for their bactericidal effect  [18, 19] . Bacte-
rial membrane damage exhibited by nostocarboline di-
mers was examined by measuring the leakage of cellular 
ATP ( table 3 ). Short-term exposure (20 min) of cultures 
of  S. aureus to NCD9 and NCD10 at 16 ! the MIC led to 
strong ATP release (30–40% of SDS-treated positive con-
trol), while at 4 ! the MIC, only a minor effect was ob-
served compared to the untreated control. Chlorhexidine 
also exhibited a concentration-dependent ATP leakage, 
while ciprofloxacin, as expected, had no short-term effect 
on membrane integrity. The observed concentration- 
dependent ATP leakage exhibited by NCD9 and NCD10 
goes parallel with the rapid concentration-dependent 
bactericidal effect and suggests that interference with 
plasma membrane integrity is at least one of the reasons 
for their bactericidal effect. 
 To test specificity for bacterial cells, the two most ac-
tive nostocarboline dimers were tested for cytotoxicity in 
CHO cells ( table 4 ). Cytotoxic activities of the nostocar-
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 CHL Fig. 1. Chemical structures of nostocar-
boline, nostocarboline homodimers and 
chlorhexidine (CHL). 
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boline dimers were relatively weak compared to the MIC 
against  S. aureus strains. NCD9 was significantly less 
toxic than NCD10 and both dimers were clearly less tox-
ic than chlorhexidine. This is in agreement with the find-
ing that NCD10 (and chlorhexidine) is active against 
yeast cells while NCD9 is not. This observation suggests 
that NCD9 with a C10 linker has better selectivity for pro-
karyotic cells than NCD10 with a C12 spacer.
 The mechanism of action of NCD9 and NCD10 was 
also tested in  E. coli reporter strains lacking the multi-
drug resistance TolC pump. The  sulA fusion strain Ec2376 
was used to detect induction of the SOS response follow-
ing DNA damage as described previously  [20] . Addition-
ally, the DegP reporter strain Ec2297 was used to monitor 
the cell envelope stress response  [21, 22] . Only NCD9 in-
duces an SOS response, albeit at a much weaker degree 
than ciprofloxacin ( fig. 2 a), whereas NCD10 (and, more 
weakly, NCD9) elicited cell envelope stress in a similar 
fashion as chlorhexidine ( fig. 2 b).
Table 3. B actericidal effect and release of cellular ATP in S. au-
reus
Compound log CFU c hange Release of cellular
ATP, % of SDS-
lysed control1 h 4 h
Untreated control +0.84 +2.07 0.5
NCD9 (4! MIC) –0.11 –0.15 4.4
NCD9 (16! MIC) –1.31 –2.61 41.1
NCD10 (4! MIC) +0.25 +0.01 2.6
NCD10 (16! MIC) –0.96 –3.28 33.2
Ciprofloxacin (4! MIC) –0.7 –2.8 0.8
Ciprofloxacin (16! MIC) –1.5 –2.6 0.7
Chlorhexidine (4! MIC) –0.14 –1.26 2.3
Chlorhexidine (16! MIC) –0.9 –4.1 9.8
ATP in supernatant was measured by luminescence assay. 
0.1% SDS was used as a membranolytic control and relative light 
units obtained were arbitrarily set as 100%.
Table 4. C ytotoxicities of selected dimers of nostocarboline com-
pared to chlorhexidine
Compound Cytotoxicity in CHO cells (IC50 in mg/l)
24 h 48 h
NCD9 >50 23.8 
NCD10 25.7 14.2 
Chlorhexidine 13.9 1.7 
Ciprofloxacin >50 >50
Da ta are averages of three determinations.
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 Fig. 2. Induction of stress response reporters by antibacterial compounds ciprofloxacin (CIP; open squares), 
chlorhexidine (CHL; filled squares), NCD9 (open triangles) and NCD10 (filled triangles). SOS induction mea-
sured in Ec2376 [  tolC   rfaC   lacZ ::( sulA’ -‘  luxCDABE )] 2 h after addition to compound ( a ) and induction of 
cell-envelope stress response in Ec2297 [  tolC   lacZ ::( degP’ -‘ luxCDABE -)] ( b ). Three independent experiments 
were performed and representative data is shown. 
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 Conclusion 
 Cationic antimicrobials are widely used as disinfec-
tants and preservatives and in topical antimicrobial prod-
ucts  [18] . On the other hand, cationic antimicrobial pep-
tide antibiotics, such as the polymyxins, have also proved 
to be useful for systemic antibacterial treatment and colis-
tin (polymyxin E) is considered as a last resort drug in the 
treatment of infections involving some multidrug-resis-
tant bacteria  [23] . While the mechanism of antibacterial 
action is not elucidated in all details, early damage to the 
cytoplasmic membrane leading to lethal effects is consid-
ered to be the common theme for this class of compounds 
 [19] . One or more strong positive charges, together with a 
hydrophobic region, are the basic structural requirements 
for membrane interaction. However, there is still contro-
versy whether other interactions including intracellular 
targets are involved, leading to the final lethal effect  [24] . 
Furthermore, the mechanism of action may vary consid-
erably within this class of compounds  [25, 26] . The low 
propensity for resistance development due to multiple tar-
get sites, the rapid bactericidal effect and the potentially 
broad antimicrobial spectrum are properties that make 
this antimicrobial class attractive for future treatment of 
bacterial infections, including bacteria resistant to all cur-
rently available antibiotics  [26, 27] . However, there are sev-
eral problems associated with the development of such 
compounds for (systemic) therapeutic use, e.g. the lack of 
specificity and consequently potentially toxic side effects, 
poor bioavailability and stability, and lack of systemic in 
vivo activity  [26–28] . In this report, we show that some 
homodimeric compounds (biscarbolines) created from 
the natural alkaloid nostocarboline display potent anti-
bacterial activity. Structurally, the nostocarboline dimers 
can be compared to bisbiguanide antiseptics, such as 
chlorhexidine, i.e. bipolar positive charges separated by a 
hydrophobic spacer region. Antimicrobial potencies and 
spectra of the dimers varied with length of the linker used 
to connect the two carbolinium moieties: the derivatives 
with linear C10- and C12-linkers were highly potent 
against Gram-positive bacteria while compounds with a 
shorter linker had only modest activities and the nosto-
carboline monomer was essentially inactive. The length of 
the hydrophobic spacer is also important for antibacterial 
activity of the bisguanides and a six carbon bridge seems 
to be ideal for activity  [19] . In contrast, quaternary am-
monium antiseptics are monocationic with a long hydro-
phobic tail. However, these compounds show dimeriza-
tion in solution and, consequently, the dimeric structure 
may be responsible for antibacterial activity. 
 The two most active nostocarboline dimers, NCD9 and 
NCD10, showed potent Gram-positive activity especially 
against  S. aureus , including multi-resistant clinical MRSA 
isolates. On the other hand, activities against Gram-nega-
tive bacteria were relatively weak, in particular against  P. 
aeruginosa . Poor penetration through the outer mem-
brane and/or intensive efflux are possible reasons for that 
finding. This notion is underscored by the strongly in-
creased activities in  E. coli efflux k.o. and outer membrane 
permeability mutants. Interestingly, NCD9 with a C10 
linker seems to act in a more specific way than NCD10 
with a C12 spacer as indicated by lower cytotoxicity and 
absence of activity against yeast strains. It is tempting to 
speculate that selectivity to bacteria versus eukaryotic cells 
may depend on the length of the linker. Preliminary inves-
tigations addressing the mode of action in bacteria suggest 
that the nostocarboline dimers act on Gram-positive bac-
teria in a similar way as chlorhexidine, i.e. by concentra-
tion-dependent membrane damage leading to leakage of 
intracellular material followed by rapid cell death. In re-
porter strains of efflux-deficient  E. coli, we found induc-
tion of DegP response pathway, consistent with the data 
above suggesting damage to the cell envelope including 
the proton motive force. It has been shown that the DegP 
expression is regulated by the CpxR regulator and depends 
on   E, which in turn can sense misfolded proteins in ex-
tracellular compartments or defects in the biogenesis of 
outer membrane proteins, respectively  [21] . It has also 
been shown that membrane-active compounds that abol-
ish the proton motive force induced the DegP-dependent 
stress response pathway  [22] . Therefore, it was quite in-
triguing to find that NCD9, but not NCD10, also induced 
the SOS response, as this would suggest that the com-
pound could interact with a cytoplasmic target as well. 
 Nostocarboline and its dimers have also shown potent 
anti-plasmodial activity  [10] , but the structure activity re-
lationship is different from the one observed in this study. 
In particular, nostocarboline was determined to possess 
submicromolar activity against  P. falciparum . The di-
mers showed consistent activity below 100 n M for dimers 
NCD6-NCD10 against this parasite. This different struc-
ture/activity relationship suggests that different modes of 
action are involved. 
 The results presented in this report indicate the poten-
tial of this new class of cationic antimicrobial compounds 
for the design of potent and selective antibacterials with 
low cytotoxicity. Further studies should involve the eval-
uation of antibacterial activity and toxicity in in vivo 
models and the design of new compounds with improved 
Gram-negative activity while optimizing selectivity. 
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